Tags: Drug.

Saxagliptin (rINN) previously identified as BMS-477118 is a new oral hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Early development was solely by Bristol-Myers Squibb; in 2007 AstraZeneca joined with Bristol-Myers Squibb to co-develop the final compound and collaborate on the marketing of the drug. In June 2008 it was announced that Onglyza would be the trade name under which saxagliptin will be marketed.In February 2014 the U.S.

Saxagliptin.svg
ATC prefix
A10
ATC suffix
BH03
CAS number
361442-04-8
DrugBank
DB06335
FDA UNII code
8I7IO46IVQ
IUPAC name
acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile, (1S3S5S)-2-[(2S)-2-amino-2-(3-hydroxy-1-adamantyl)
PubChem
11243969

Loading...

This page contains content from the copyrighted Wikipedia article "Saxagliptin"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.